EUCTR2013-004620-10-SE进行中（未招募）1 期
A double blind, placebo controlled randomized study of nasal steroid spray treatment on the quality of life and objective sleep parameters in children with sleep disorder breathing.
Johan Hellgren0 个研究点开始时间: 2014年10月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Children 4-10 years old
- •Valid address in Sweden 2015-16
- •Snoring and/or apneas during at least 3 months
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 60
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Lack of ability to read and write Swedish
- •Acute respiratory infection
- •Use of nasal or systemic corticosteroids or antibiotics within 4 wks prior to study
- •Prior tonsil or adenoid surgery
- •History of craniofacial, neuromuscular or genetic disorders
- •Severe obstructive sleep apnea (OSA) requiring urgent surgery
- •No interest in participating in study
研究者
相似试验
已完成
不适用
Risperidone in children and adolescents with aggressive behaviourConduct disorder / Oppositional Defiant DisorderMental and Behavioural DisordersConduct disordersISRCTN95429815Radboud University Nijmegen Medical Centre (Netherlands)264
进行中（未招募）
不适用
A randomized double blind, placebo controlled study to evaluate the efficacy and security of immunotherapy with a depigmented and polymerized allergen extract of Dermatophagoides pteronyssinus in patients with asthma.Mild to moderate asthma caused by sensitization againts dust mite Dermatophagoides Pteronyssinus.MedDRA version: 9.1Level: LLTClassification code 10001705Term: Allergic asthmaEUCTR2006-000602-23-PTaboratorios LETI S.L.
尚未招募
3 期
A randomized double blind, placebo-controlled study of fluoxetine in progressive multiple sclerosis (FLUOX-PMS)NL-OMON37668Prof. dr. J. de Keyser, Neurologie, UZ Brussel10
进行中（未招募）
不适用
Safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of QBW251 in healthy subjects and cystic fibrosis patients.MedDRA version: 16.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disorderscystic fibrosisEUCTR2011-005085-37-IEovartis Pharma Services AG156
进行中（未招募）
不适用
Safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of QBW251 in healthy subjects and cystic fibrosis patients.cystic fibrosisEUCTR2011-005085-37-FRovartis Pharma Services AG140